Compendium of Cancer Genome Aberrations

BRST5:Tall cell carcinoma with reversed polarity: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
Repeat columns removed
added gene diagram
Line 2: Line 2:


[[BRST5:Table_of_Contents|Breast Tumours (WHO Classification, 5th ed.)]]
[[BRST5:Table_of_Contents|Breast Tumours (WHO Classification, 5th ed.)]]
{{Under Construction}}
<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>
==Primary Author(s)*==
==Primary Author(s)*==
H. Evin Gulbahce, MD, MSCI, University of Utah, UT, USA <span style="color:#0070C0"> </span>
H. Evin Gulbahce, MD, MSCI, University of Utah, UT, USA <span style="color:#0070C0"> </span>
Line 31: Line 27:


==WHO Essential and Desirable Genetic Diagnostic Criteria==
==WHO Essential and Desirable Genetic Diagnostic Criteria==
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
{| class="wikitable"
{| class="wikitable"
|+
|+
Line 40: Line 33:
|-
|-
|WHO Desirable Criteria (Genetics)*
|WHO Desirable Criteria (Genetics)*
|
|''IDH2'' mutation
|-
|-
|Other Classification
|Other Classification
Line 47: Line 40:
<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
==Related Terminology==
==Related Terminology==
<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
{| class="wikitable"
{| class="wikitable"
|+
|+
Line 121: Line 111:


==Gene Mutations (SNV/INDEL)==
==Gene Mutations (SNV/INDEL)==
[[File:IDH2 with protein domain and hotspots.png|left|thumb|769x769px|Diagram of the ''IDH2'' gene (NM_002168) showing the mutational hotspot R172 within the isocitrate dehydrogenase functional domain. Missense mutations at codon 172 result in a substitution for arginine (R) with a different amino acid. Image prepared with the aid of ProteinPaint {26711108} and BioRender software <nowiki>[https://BioRender.com, accessed on 11/4/2025]</nowiki>.]]
<br />
<br />
{| class="wikitable sortable"
{| class="wikitable sortable"
Line 146: Line 137:
|Co-mutated with ''IDH2''; hotspots include H1047R, E542K, E545K<ref name=":0" />
|Co-mutated with ''IDH2''; hotspots include H1047R, E542K, E545K<ref name=":0" />
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


==Epigenomic Alterations==
==Epigenomic Alterations==
Retrieved from "https://test.ccga.io/index.php/BRST5:Tall_cell_carcinoma_with_reversed_polarity"